Antimicrobial Resistance in the Intensive Care Unit: Mechanisms, Epidemiology, and Management of Specific Resistant Pathogens

Critical Care Clinics

Volumn 27, Issue 1, 2011, Pages 163-205

  Fraimow, Henry S ^a   Tsigrelis, Constantine ^a  

^a Department of Anesthesiology   (United States)

Author keywords

Gram negative bacteria; Mechanisms; Methicillin resistant Staphylococcus aureus; Multidrug resistance; Resistance; Vancomycin resistant enterococci

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM; BETA LACTAMASE; CARBAPENEM; CEFTAROLINE; CEPHALOSPORIN; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; ISONIAZID; LINEZOLID; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; PENICILLIN G; PENICILLINASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; ENDOCARDITIS; ENTEROBACTER; ENTEROCOCCAL INFECTION; HEALTH CARE SYSTEM; HOSPITAL; HUMAN; INFECTION; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIAL GENETICS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NECROTIZING FASCIITIS; NEPHROTOXICITY; NONHUMAN; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; PROSTHETIC VALVE DYSFUNCTION; PSEUDOMONADACEAE; REVIEW; SALVAGE THERAPY; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS;

EID: 78649942813     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.11.002     Document Type: Review

References (205)

1. Boucher H.W., Talbot G.H., Bradley J.S., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
2. European Centre for Disease Prevention and Control/European Medicines Agency Joint Technical Report The bacterial challenge: time to react Available at:, Accessed September 9, 2009. http://www.emea.europa.eu/pdfs/human/antimicrobial_resistance/EMEA-576176-2009.pdf.
3. Livermore D.M. Has the era of untreatable infections arrived?. J Antimicrob Chemother 2009, 64:i29-i36.
4. Esposito S., Leone S. Antimicrobial treatment for intensive care unit (ICU) infections including the role of the infectious disease specialist. Int J Antimicrob Agents 2007, 29:494-500.
5. International Organization for Standards. 15 November 2006, posting date. Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility testing devices. 1. Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. ISO 20776-1. International Organization for Standardization (ISO). Geneva, Switzerland.
6. Woodford N., Sundsfjord A. Molecular detection of antibiotic resistance: when and where?. J Antimicrob Chemother 2005, 56:259-261.
7. Martínez J.L., Baquero F., Andersson D.I. Predicting antibiotic resistance. Nat Rev Microbiol 2007, 5:958-965.
8. Plesiat P. Biochemistry of resistance. Antibiogram 2010, 17-24. Eska Publishing, ASM Press, Portland (OR). P. Courvalin, R. Leclercq, L.B. Rice (Eds.).
9. Jacoby G.A., Munoz-Price L.S. The new β-lactamases. N Engl J Med 2005, 352:380-391.
10. Andersson D.I., Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance?. Nat Rev Microbiol 2010, 8:260-271.
11. Rice L.B. Genetics of resistance. Antibiogram 2010, 25-36. Eska Publishing, ASM Press, Portland (OR). P. Courvalin, R. Leclercq, L.B. Rice (Eds.).
12. Périchon B., Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53:4580-4587.
13. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005, 56:20-51.
14. Falagas M.E., Koletsi P.K., Bliziotis I.A. The diversity of definitions of multidrug-resistant and pandrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006, 55:1619-1629.
15. Chambers H.F., Deleo F.R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009, 7:629-641.
16. Boyce J.M., Causey W.A. Increasing occurrence of methicillin-resistant Staphylococcus aureus in the United States. Infect Control 1982, 3:377-383.
17. Klevens R.M., Edwards J.R., Tenover F.C., National Nosocomial Infections Surveillance System, et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006, 42:389-391.
18. Boucher H.W., Corey R.G. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008, 46:S344-S349.
19. Moran G.J., Krishnadasan A., Gorwitz R.J., et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006, 355:666-674.
20. Seybold U., Kourbatova E.V., Johnson J.G., et al. Emergence of community associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006, 42:647-656.
21. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001, 1:147-155.
22. Sánchez García M., De la Torre M.A., Morales G., et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010, 303:2260-2264.
23. Boucher H.W., Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007, 45:601-608.
24. Klevens R.M., Morrison M.A., Nadle J., Active Bacterial Core Surveillance (ABCs) MRSA Investigators, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763-1771.
25. Cosgrove S.E., Qi Y., Kaye K.S., et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005, 26:166-174.
26. Filice G.A., Nyman J.A., Lexau C., et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol 2010, 31:365-373.
27. Kallen A.J., Mu Y., Bulens S., et al. Health care-associated Invasive MRSA infections, 2005-2008. JAMA 2010, 304:641-648.
28. US Department of Health and Human Services HHS action plan to prevent healthcare-associated infections Avaialble at:, Accessed September 7, 2010. http://www.hhs.gov/ophs/initiatives/hai/infection.html.
29. Burton D.C., Edwards J.R., Horan T.C., et al. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009, 301:727-736.
30. Perencevich E.N., Dikema D.J. Decline in invasive MRSA infection: Where to go from here?. JAMA 2010, 304:687-689.
31. European Antimicrobial Resistance Surveillance System (EARSS) Annual Report 2008. Vol 2010 2008, EARSS, Bilthoven (the Netherlands), Available at:, Accessed September 7, 2010. http://www.rivm.nl/earss/Images/EARSS%202008_final_tcm61-65020.pdf.
32. Herold B.C., Immergluck L.C., Maranan M.C., et al. Community-acquired methicillin resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998, 279:593-598.
33. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. JAMA 1999, 282:1123-1125.
34. Udo E.E., Pearman J.W., Grubb W.B. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993, 25:97-108.
35. Martinez-Aguilar G., Avalos-Mishaan A., Hulten K., et al. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004, 23:701-706.
36. David M.Z., Daum R.S. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010, 23:616-687.
37. Gordon R.J., Lowy F.D. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008, 46:S350-S359.
38. Kirst H.A., Thompson D.G., Nicas T.I. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998, 42:1303-1304.
39. Howden B.P., Davies J.K., Johnson P.D., et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010, 23:99-139.
40. Tenover F.C., Moellering R.C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007, 44:1208-1215.
41. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement. CLSI document M100-S20 2010, Clinical and Laboratory Standards Institute, Wayne (PA).
42. Liu C., Chambers H.F. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003, 47:3040-3045.
43. Wang G., Hindler J.F., Ward K.W., et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006, 44:3883-3886.
44. Rybak M.J., Lomaestro B.M., Rotschafer J.C., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327.
45. Lodise T.P., Graves J., Graffunder E., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320.
46. Lodise T.P., Lomaestro B., Graves J., et al. Larger vancomycin doses (≥4 grams/day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008, 52:1330-1336.
47. Farrell D.J., Mendes R.E., Ross J.E., et al. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis 2009, 65:392-403.
48. Long K.S., Poehlsgaard J., Kehrenberg C., et al. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 2006, 50:2500-2505.
49. Fraimow H.S. Lipopeptides, lipoglycopeptides and glycolipodepsipeptides. Antibiogram 2010, 295-304. Eska Publishing, ASM Press, Portland (OR). P. Courvalin, R. Leclercq, L.B. Rice (Eds.).
50. Moise P.A., North D., Steenbergen J.N., et al. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009, 9:617-624.
51. Moise P.A., Hershberger E., Amodio-Groton M.I., et al. Safety and clinical outcomes when utilizing high-dose (> or = 8 mg/kg) daptomycin therapy. Ann Pharmacother 2009, 43:1211-1219.
52. Putnam S.D., Sader H.S., Farrell D.J., et al. Sustained antimicrobial activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States Medical Centers from 2004 through 2008. J Chemother 2010, 22:13-16.
53. Gardiner D., Dukart G., Cooper A., et al. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 2010, 50:229-238.
54. Nace H., Lorber B. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin. J Antimicrob Chemother 2010, 65:1315-1316.
55. Fowler V.G., Boucher H.W., Corey G.R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665.
56. Falagas M.E., Manta K.G., Ntziora F., et al. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006, 58:273-280.
57. Baddour L.M., Wilson W.R., Bayer A.S., et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals. Circulation 2005, 11:e394-e434.
58. Hawkey P.M. Pre-clinical experience with daptomycin. J Antimicrob Chemother 2008, 62(Suppl 3):7-14.
59. American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 17:388-416.
60. Wunderink R.G., Rello J., Cammarata S.K., et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124:1789-1797.
61. Wiersma P., Tobin D'Angelo M., Daley W.R., et al. Surveillance for severe community-associated methicillin-resistant Staphylococcus aureus infection. Epidemiol Infect 2009, 137:1674-1678.
62. Stevens D.L., Ma Y., Salmi D.B., et al. Impact of antibiotics on the expression of virulence-associated exotoxin genes in methicillin-sensitive and in methicillin-resistant Staphylococcus aureus. J Infect Dis 2007, 195:202-211.
63. Nathwani D., Morgan M., Masterson R.G., et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 2008, 61:976-994.
64. Weigelt J., Itani K., Stevens D., et al. Linezolid versus vancomycin in the treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005, 49:2260-2266.
65. Arbeit R.D., Maki D., Tally F.P., et al. The safety and efficacy of daptomycin for the treatment of complicated skin and soft tissue infection. Clin Infect Dis 2004, 38:1673-1681.
66. Florescu I., Beuran M., Dimov R., et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008, 62(Suppl 1):i17-i28.
67. Han L.L., McDougal L.K., Gorwitz R.J., et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol 2007, 45:1350-1352.
68. Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2009, 49:1072-1079.
69. Cosgrove S.E., Vigliani G.A., Fowler V.G., et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009, 48:713-721.
70. Perlroth J., Kuo M., Tan J., et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008, 168:805-819.
71. Jang H.C., Kim S.H., Kim K.H., et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009, 49:395-401.
72. Steenbergen J.N., Mohr J.F., Thorne G.M. Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother 2009, 64:1130-1138.
73. Hidron A.I., Edwards J.R., Patel J., National Healthcare Safety Network Team, Participating National Healthcare Safety Network Facilities, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011.
74. Donskey C.J., Chowdhry T.K., Hecker M.T., et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000, 343:1925-1932.
75. Arias C.A., Murray B.E. Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther 2008, 6:637-655.
76. Murray B.E. Beta-lactamase-producing enterococci. Antimicrob Agents Chemother 1992, 36:2355-2359.
77. Rybkine T., Mainardi J.L., Sougakoff W., et al. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance. J Infect Dis 1998, 178:159-163.
78. Rice L.B., Carias L.L., Rudin S., et al. Enterococcus faecium low-affinity pbp5 is a transferable determinant. Antimicrob Agents Chemother 2005, 49:5007-5012.
79. National Nosocomial Infections Surveillance System National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004, 32:470-485.
80. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC) Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1995, 44(RR-12):1-13.
81. Siegel J.D., Rhinehart E., Jackson M., Healthcare Infection Control Practices Advisory Committee, et al. Management of multidrug-resistant organisms in healthcare settings 2006, Centers for Disease Control and Prevention, Atlanta (GA).
82. Fraimow H.S., Courvalin P. Resistance to glycopeptides in gram-positive pathogens. Gram positive pathogens 2006, 782-800. ASM Press, Washington, DC. 2nd edition. V.A. Fischetti, R.P. Novick, J.J. Ferretti (Eds.).
83. Arias C.A., Contreras G.A., Murray B.E. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010, 16:555-562.
84. Herrero I.A., Issa N.C., Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002, 346:867-869.
85. Scheetz M.H., Knechtel S.A., Malczynski M., et al. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrobial Agents Chemother 2008, 52:2256-2259.
86. Eliopolous G.M. Aminoglycoside resistant enterococcal endocarditis. Infect Dis Clin North Am 1993, 7:117-133.
87. Gavaldà J., Len O., Miró J.M., et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007, 146:574-579.
88. Centers for Disease Control and Prevention Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, provisional-2009 Available at:, Accessed September 9, 2010. http://www.cdc.gov/abcs/reports-findings/survreports/spneu09.pdf.
89. Liñares J., Ardanuy C., Pallares R., et al. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010, 16:402-410.
90. Reinert R.R. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect 2009, 15:S7-11.
91. Dagan R., Klugman K.P. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 2008, 8:785-795.
92. Canton R., Morosini M., Enright M.C., et al. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003, 2:944-952.
93. Delcour A.H. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta 2009, 1794:808-816.
94. Donnenberg M.S. Enterobacteriaceae. Mandell, Douglas, and Bennett's principles and practice of infectious diseases 2010, 2815-2817. Churchill Livingstone Elsevier, Philadelphia. 7th edition. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
95. Hooper D.C. Efflux pumps and nosocomial antibiotic resistance: a primer for hospital epidemiologists. Clin Infect Dis 2005, 40:1811-1817.
96. Chambers H.F. Penicillins and β-lactam inhibitors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases 2010, 309-322. Churchill Livingstone Elsevier, Philadelphia. 7th edition. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
97. Poole K. Resistance to beta-lactam antibiotics. Cell Mol Life Sci 2004, 61:2200-2202.
98. Bush K., Jacoby G.A. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010, 54:969-976.
99. Paterson D.L. Resistance in gram-negative bacteria: enterobacteriaceae. Am J Med 2006, 119:S20-S28.
100. Livermore D.M. Defining an extended-spectrum beta-lactamase. Clin Microbiol Infect 2008, 14:S3-10.
101. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
102. Queenan A.M., Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007, 20:440-458.
103. Jacoby G.A. AmpC beta-lactamases. Clin Microbiol Rev 2009, 22:161-182.
104. Robicsek A., Jacoby G.A., Hooper D.C. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006, 6:629-640.
105. Jacoby G.A. Mechanisms of resistance to quinolones. Clin Infect Dis 2005, 41:S120-S126.
106. Strahilevitz J., Jacoby G.A., Hooper D.C., et al. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 2009, 22:664-689.
107. Vakulenko S.B., Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 2003, 16:430-450.
108. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005, 49:479-487.
109. Michalopoulos A., Falagas M.E. Colistin and polymyxin B in critical care. Crit Care Clin 2008, 24:377-391.
110. Nation R.L., Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009, 22:535-543.
111. Livermore D.M. Tigecycline: what is it, and where should it be used?. J Antimicrob Chemother 2005, 56:611-614.
112. Giamarellou H., Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options?. Drugs 2009, 69:1879-1901.
113. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; Ninth informational supplement, CLSI document M100-S9 1999, Clinical and Laboratory Standards Institute, Wayne (PA).
114. Moland E.S., Hanson N.D., Black J.A., et al. Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. J Clin Microbiol 2006, 44:3318-3324.
115. Rosenthal V.D., Maki D.G., Jamulitrat S., INICC Members, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am J Infect Control 2010, 38:95-104. e2.
116. Zhanel G.G., Decorby M., Nichol K.A., et al. Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: results of the Canadian National Intensive Care Unit Study (2005-2006). Can J Infect Dis Med Microbiol 2008, 19:243-249.
117. Zhanel G.G., DeCorby M., Laing N., Canadian Antimicrobial Resistance Alliance (CARA), et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother 2008, 52(7):1430.
118. Pitout J.D. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010, 70:313-333.
119. Paterson D.L., Ko W.C., Von Gottberg A., et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004, 39:31-37.
120. Endimiani A., Luzzaro F., Perilli M., et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004, 38:243-251.
121. Kang C.I., Kim S.H., Park W.B., et al. Bloodstream infections due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004, 48:4574-4581.
122. Zanetti G., Bally F., Greub G., Cefepime Study Group, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003, 47:3442-3447.
123. Peterson L.R. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect 2008, 14:S181-S184.
124. Gavin P.J., Suseno M.T., Thomson R.B., et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 2006, 50:2244-2247.
125. Rodríguez-Baño J., Navarro M.D., Romero L., et al. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006, 43:1407-1414.
126. Tumbarello M., Spanu T., Sanguinetti M., et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006, 50:498-504.
127. Paterson D.L., Ko W.C., Von Gottberg A., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001, 39:2206-2212.
128. Kotapati S., Kuti J.L., Nightingale C.H., et al. Clinical implications of extended spectrum beta-lactamase producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infect 2005, 51:211-217.
129. Wong-Beringer A., Hindler J., Loeloff M., et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002, 34:135-146.
130. Goethaert K., Van Looveren M., Lammens C., et al. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect 2006, 12:56-62.
131. Labombardi V.J., Rojtman A., Tran K. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Diagn Microbiol Infect Dis 2006, 56:313-315.
132. Bin C., Hui W., Renyuan Z., et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 2006, 56:351-357.
133. Bhat S.V., Peleg A.Y., Lodise T.P., et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother 2007, 51:4390-4395.
134. Lee S.Y., Kuti J.L., Nicolau D.P. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. J Infect 2007, 54:463-468.
135. Endimiani A., Perez F., Bonomo R.A. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther 2008, 6:805-824.
136. Thomson K.S., Moland E.S. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001, 45:3548-3554.
137. Craig W.A., Bhavnani S.M., Ambrose P.G. The inoculum effect: fact or artifact?. Diagn Microbiol Infect Dis 2004, 50:229-230.
138. Kim Y.K., Pai H., Lee H.J., et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002, 46:1481-1491.
139. Kaye K.S., Cosgrove S., Harris A., et al. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001, 45:2628-2630.
140. Chow J.W., Fine M.J., Shlaes D.M., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115:585-590.
141. Choi S.H., Lee J.E., Park S.J., et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother 2008, 52:995-1000.
142. Nordmann P., Cuzon G., Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009, 9:228-236.
143. Bratu S., Tolaney P., Karumudi U., et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005, 56:128-132.
144. Yong D., Toleman M.A., Giske C.G., et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009, 53:5046-5054.
145. Kumarasamy K.K., Toleman M.A., Walsh T.R., et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602.
146. Centers for Disease Control and Prevention (CDC) Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase-United States, 2010. MMWR Morb Mortal Wkly Rep 2010, 59:750.
147. Rolain J.M., Parola P., Cornaglia G. New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia?. Clin Microbiol Infect 2010 Sep 27, 10.1111/j.1469-0691.2010.03385.x.
148. Peleg A.Y., Hooper D.C. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010, 362:1804-1813.
149. Elemam A., Rahimian J., Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 2009, 49:271-274.
150. Endimiani A., Hujer A.M., Perez F., et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother 2009, 63:427-437.
151. Lee J., Patel G., Huprikar S., et al. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol 2009, 47:1611-1612.
152. Walkty A., DeCorby M., Nichol K., et al. In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008. Antimicrob Agents Chemother 2009, 53:4924-4926.
153. Daly M.W., Riddle D.J., Ledeboer N.A., et al. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 2007, 27:1052-1057.
154. Anthony K.B., Fishman N.O., Linkin D.R., et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008, 46:567-570.
155. Castanheira M., Sader H.S., Deshpande L.M., et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008, 52:570-573.
156. Kelesidis T., Karageorgopoulos D.E., Kelesidis I., et al. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008, 62:895-904.
157. McGowan J.E. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med 2006, 119(6 Suppl 1):S29-S36.
158. Lister P.D., Wolter D.J., Hanson N.D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009, 22:582-610.
159. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008, 21:538-582.
160. Denton M., Kerr K.G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998, 11:57-80.
161. Streit J.M., Jones R.N., Sader H.S., et al. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004, 24:111-118.
162. Livermore D.M. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001, 47:247-250.
163. Bonomo R.A., Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006, 43:S49-S56.
164. Toleman M.A., Bennett P.M., Bennett D.M., et al. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis 2007, 13:559-565.
165. Kallen A.J., Hidron A.I., Patel J., et al. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol 2010, 31:528-531.
166. Mandell L. Doripenem: a new carbapenem in the treatment of nosocomial infection. Clin Infect Dis 2009, 49:S1-S3.
167. Peleg A.Y., Potoski B.A., Rea R., et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007, 59:128-131.
168. Fishbain J., Peleg A.Y. Treatment of Acinetobacter infections. Clin Infect Dis 2010, 51:79-84.
169. Petrosillo N., Ioannidou E., Falagas M.E. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008, 14:816-827.
170. Nicodemo A.C., Paez J.I. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007, 26:229-237.
171. Falagas M.E., Valkimadi P.E., Huang Y.T., et al. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother 2008, 62:889-894.
172. Insa R., Cercenado E., Goyanes M.J., et al. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 2007, 59:583-585.
173. Wexler H.M. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 2007, 20:593-621.
174. Garrett W.S., Onderdonk A.B. Bacteroides, Prevotella, Porphyromonas, and Fusobacterium species (and other medically important anaerobic gram-negative bacilli). Mandell, Douglas, and Bennett's principles and practice of infectious diseases 2010, 3111-3119. Churchill Livingstone Elsevier, Philadelphia. 7th edition. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
175. Snydman D.R., Jacobus N.V., McDermott L.A., et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis 2010, 50:S26-S33.
176. Nagy E., Urbán E., Carl Erik Nord on behalf of the ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 2010, [Epub ahead of print].
177. National Conference of State Legislatures Healthcare-Associated Infections Homepage Healthcare-Associated Infections Homepage Available at:, Accessed September 10, 2010. http://www.ncsl.org/default.aspx%3Ftabid%3D14084.
178. CDC Campaign to prevent antimicrobial resistance in healthcare settings Available at:, Accessed September 10, 2010. http://www.cdc.gov/drugresistance/healthcare/ha/12steps_HA.htm.
179. Fridkin S.K., Steward C.D., Edwards J.R., et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Clin Infect Dis 1999, 29:245-252.
180. Rogues A.M., Dumartin C., Amado B., et al. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol 2007, 28:1389-1395.
181. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
182. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
183. Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America: guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
184. Beardsley J., Williamson J., Johnson J., et al. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital acquired pneumonia. Chest 2006, 130:787-793.
185. Ibrahim E.H., Ward S., Sherman G., et al. Experience with a clinical guideline for the treatment of ventilator associated pneumonia. Crit Care Med 2001, 29:1109-1115.
186. Gandhi T.N., DePestel D.D., Collins C.D., et al. Managing antimicrobial resistance in intensive care units. Crit Care Med 2010, 38:S315-S323.
187. Singh N., Rogers P., Atwood C.W., et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162:505-511.
188. Bouadma L., Luyt C.E., Tubach F., et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474.
189. Schuetz P., Christ-Crain M., Thomann R., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066.
190. Lodise T.P., Lomaestro B.M., Drusano G.L. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006, 26:1320-1332.
191. Chastre J., Wolff M., Fagon J.Y., et al. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290:2588-2598.
192. Niederman M.S. Use of broad-spectrum antimicrobials for treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 2006, 42:S72-S81.
193. Kollef M.H. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit?. Clin Infect Dis 2006, 43:S82-S88.
194. Chittick P., Sherertz R.J. Recognition and prevention of nosocomial vascular device and related bloodstream infections in the intensive care unit. Crit Care Med 2010, 38:S363-S372.
195. Shuman E.K., Chenoweth C.E. Recognition and prevention of healthcare-associated urinary tract infections in the intensive care unit. Crit Care Med 2010, 38:S373-S379.
196. Gastmeier P. Evidence-based infection control in the ICU (except catheters). Curr Opin Crit Care 2007, 13:557-562.
197. Lin M.Y., Hayden M.K. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: recognition and prevention in intensive care units. Crit Care Med 2010, 38:S335-S344.
198. Tschudin-Sutter S., Pargger H., Widmer A.F. Hand hygiene in the intensive care unit. Crit Care Med 2010, 38:S299-S305.
199. Vernon M.O., Hayden M.K., Trick W.E., et al. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 2006, 166:306-312.
200. Climo M.W., Sepkowitz K.A., Zuccotti G., et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococcus, and healthcare associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 2009, 37:1858-1865.
201. Huskins W.C. Interventions to prevent transmission of antimicrobial-resistant bacteria in the intensive care unit. Curr Opin Crit Care 2007, 13:572-577.
202. Tacconelli E., De Angelis G., de Waure C., et al. Rapid screening tests for methicillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:546-554.
203. Lucet J.C., Regnier B. Screening and decolonization: does methicillin-susceptible Staphylococcus aureus hold lessons for methicillin-resistant S. aureus?. Clin Infect Dis 2010, 51:585-590.
204. Ammerlaan H.S., Kluytmans J.A., Wertheim H.F., et al. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis 2009, 48:922-930.
205. Simor A.E., Phillips E., McGeer A., et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007, 44:178-185.